GlassScriptPhysician profile
Jennifer D Nardone
NPI 1316217029
$11,290.17
in general payments reported to CMS, 2019-2025
33 companies · $2,692 in 2025
The $2,692 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,176 · 2022: $1,727 · 2023: $2,436 · 2024: $3,260 · 2025: $2,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,033 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,033.34 |
| Education | $353.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,366.35 | 2021-2025 | |
| Janssen Biotech, INC. | $1,159.07 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $966.72 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Lilly USA, LLC | $961.95 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $893.72 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Regeneron Healthcare Solutions, INC. | $729.08 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $662.12 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $618.51 | 2022-2025 | Sotyktu |
| Amgen INC. | $590.94 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $478.29 | 2022-2025 | Opzelura, Niktimvo |
| Ucb, INC. | $394.43 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $366.59 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $360.68 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $320.72 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $307.09 | 2021-2025 | Jublia, Arazlo, Cabtreo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $168.16 | 2021-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $140.49 | 2022-2024 | Vtama |
| Genzyme Corporation | $137.46 | 2021-2025 | |
| Journey Medical Corporation | $120.09 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Convatec INC. | $77.05 | 2025 | |
| Epi Health, LLC | $55.82 | 2021-2022 | |
| Organon LLC | $45.36 | 2025 | Nexplanon, Vtama |
| Leo Pharma INC. | $45.01 | 2021-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.85 | 2022 | |
| Botanix Sb INC | $36.48 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $28.99 | 2025 | Xtrac |
| Genentech USA, INC. | $28.06 | 2023-2024 | Erivedge |
| Biofrontera INC. | $25.89 | 2021 | |
| Biocon Biologics INC | $16.96 | 2025 | Yesintek |
| Blueprint Medicines Corporation | $15.69 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $14.71 | 2022 | |
| Vyne Pharmaceuticals INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Nardone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.